Table 1.
Genetic landscape of cholangiocarcinoma.
| Acronym | Full Name | Incidence (%) |
|---|---|---|
| APC | Adenomatous polyposis coli | 15 |
| ARID1A | AT-rich interaction domain 1A | 25 |
| AKT1 | Homologue retrovirus kinase isolated from AKT-8(-1) | <5 |
| AXIN1 | Axis inhibition protein 1 | 40 |
| BAP1 | BRCA1-associated protein 1 | 25 |
| BRAF | v-raf murine sarcoma viral oncogene homolog B1 | 20 |
| BRCA1 | Breast Cancer gene 1 | <1 |
| BRCA2 | Breast Cancer gene 2 | 3 |
| CDKN2A/B | Cyclin-dependent kinase inhibitor 2A/B | 15 |
| CTNNB1 | Catenin Beta 1 | 8 |
| c-MET | Cellular-mesenchymal epithelial transition factor | <5 |
| EGFR | Epidermal growth factor receptor | 20 |
| FGFR2 | Fibroblast growth factor receptor 2 | 15 |
| HER2 | Human epidermal growth factor receptor 2 | <10 |
| IDH1/2 | Isocitrate dehydrogenase 1/2 | 15 |
| KRAS | Kirsten rat sarcoma viral oncogene homolog | 20 |
| MEK | Mapk/erk kinase | 15 |
| NTRK | Neurotrophic tyrosine receptor kinase | <1 |
| PIK3CA | Phosphatidylinotitol 3-kinase catalytic subunit alpha | 15 |
| ROS1 | ROS proto-oncogene 1 | 10 |
| SMAD4 | Mothers against decapentaplegic homolog 4 | 25 |
| TP53 | Tumor protein 53 | 35 |
| VEGF | Vascular endothelial growth factor | 15 |